EyePoint Pharmaceuticals: Funding, Investors & Team (Sep 2026)
EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.
EyePoint Pharmaceuticals has raised $45.0M across 1 funding round on record, the most recent a Post-IPO Debt of $45.0M announced in Mar 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EyePoint Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2022.
EyePoint Pharmaceuticals Funding Rounds
EyePoint Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
EyePoint Pharmaceuticals Funding Compared to Other Biotechnology Startups
EyePoint Pharmaceuticals' latest round of $45.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EyePoint Pharmaceuticals in Biotechnology and Watertown
Companies Similar to EyePoint Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
EyePoint Pharmaceuticals Funding FAQs
What does EyePoint Pharmaceuticals do?
EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.
How much funding has EyePoint Pharmaceuticals raised?
EyePoint Pharmaceuticals has raised $45.0M across 1 round on record. The most recent is a Post-IPO Debt of $45.0M announced in Mar 2022.
When did EyePoint Pharmaceuticals last raise funding?
EyePoint Pharmaceuticals' most recent funding round on record is a Post-IPO Debt of $45.0M, announced in Mar 2022.
Who is the CEO of EyePoint Pharmaceuticals?
Paul Ashton is listed as CEO at EyePoint Pharmaceuticals.
Where is EyePoint Pharmaceuticals headquartered?
EyePoint Pharmaceuticals is based in Watertown, Massachusetts, United States.
How many employees does EyePoint Pharmaceuticals have?
EyePoint Pharmaceuticals is in the 101-250 employee band.
How does EyePoint Pharmaceuticals' funding compare to other Biotechnology startups?
EyePoint Pharmaceuticals' latest round of $45.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's EyePoint Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EyePoint Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.